SeQuent Scientific, having businesses in animal health sector through its principal operating company Alivira Animal Health, has completed the acquisition of a 100% stake in Nourrie Saúde e Nutrição Animal Ltda (Nourrie) in Brazil. This acquisition has been made through Alivira Saúde Animal Ltda Brazil, a wholly owned subsidiary of Alivira, for a total cash consideration of US $ 5 million.

SeQuent had originally announced the signing of the binding agreement to acquire Nourrie on 16^th December 2021. The conclusion of Nourrie’s acquisition marks an important milestone in Sequent 2.0 strategy of establishing a presence in Brazil’s pet market, the fastest-growing segment. Brazil has the 4^th largest pet market in the world with estimated market size of BRL 1.8 Billion, growing annually at 16%. 

The addition of Nourrie’s business has nearly doubled the product portfolio available to Alivira for commercialization in Brazil, with additions in both the nutraceutical and therapeutic product categories. Nourrie also brings a strong pipeline of 20 products under development, 12 of which are planned for launch in the next fiscal. 

The acquisition also provides Alivira complete control over the value-chain of Transuin, a Ractopamine based swine product currently manufactured at Nourrie, which is at present the 3^rd largest product in Alivira Brazil’s portfolio. With access to Alivira’s own API manufactured in the USFDA approved plant at Vizag, and extension of product range with upcoming registration approvals, Alivira intends to fast-track growth for Transuin franchise in both Brazil and other Latam markets. The expansion of swine and poultry segment will be further catalysed with nearly 5 new product launches expected in the near term.

Consequent to the oversight of Alivira management, Nourrie’s pet business outlook has been promising, with monthly revenues having grown by 50%+ in February 2022, compared to those at the time of acquisition announcement in December 2021. Alivira already has an established track-record of performance in Brazil, with the local operations growing 5-fold at a CAGR of 57% over last 5 years.  Brazil has emerged as the third largest market for Alivira, next only to Spain and Turkey.